Permanent neonatal diabetes mellitus: Same mutation, different glycemic control with sulfonylurea therapy on long-term follow-up

JCRPE Journal of Clinical Research in Pediatric Endocrinology

Volumn 4, Issue 2, 2012, Pages 107-110

  Aydin, Banu Küçükemre ^a   Bundak, Rüveyde ^a   Baş, Firdevs ^a   Maraş, Hülya ^a   Saka, Nurçin, ^a   Günöz, Hülya ^a   Darendeliler, Feyza ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

ABCC8; Diabetes mellitus; Sulfonylurea; SUR1

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; C PEPTIDE; GLIBENCLAMIDE; GLUCAGON; GLUCOSE; GLUTAMIC ACID; HEMOGLOBIN A1C; INSULIN; ISOPHANE INSULIN; LYSINE; NUCLEOTIDE; SULFONYLUREA; SULFONYLUREA RECEPTOR 1;

ABSENCE OF SIDE EFFECTS; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CASE REPORT; CODON; DIABETES MELLITUS; DIET THERAPY; DRUG DOSE INCREASE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXON; FOCAL EPILEPSY; FOLLOW UP; GENE IDENTIFICATION; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HETEROZYGOTE; HUMAN; INFANT; INSULIN TREATMENT; LABORATORY TEST; LENGTH OF STAY; MALE; METABOLIC REGULATION; MISSENSE MUTATION; NEWBORN DISEASE; PATIENT COMPLIANCE; PERMANENT NEONATAL DIABETES MELLITUS; SEQUENCE ANALYSIS; SIBLING; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; WEIGHT GAIN;

ATP-BINDING CASSETTE TRANSPORTERS; BLOOD GLUCOSE; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUTATION; PEDIGREE; POTASSIUM CHANNELS, INWARDLY RECTIFYING; RECEPTORS, DRUG; SIBLINGS; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME;

EID: 84862905284     PISSN: 13085727     EISSN: 13085735     Source Type: Journal    
DOI: 10.4274/Jcrpe.524     Document Type: Article

References (19)

1. Rubio-Cabezas O, Klupa T, Malecki MT, CEED3 Consortium. Permanent neonatal diabetes mellitus the importance of diabetes differential diagnosis in neonates and infants. Eur J Clin Invest 2011;41:323-333.
2. Abaci A, Razi CH, Ozdemir O, Hizli S, Kislal F, Agras PI, Kabakus N. Neonatal diabetes mellitus accompanied by diabetic ketoacidosis and mimicking neonatal sepsis: A case report. J Clin Res Pediatr Endocrinol 2010;2:131-133.
3. Edghill EL, Flanagan SE, Patch AM, Boustred C, Parrish A, Shields B, Shepherd MH, Hussain K, Kapoor RR, Malecki M, MacDonald MJ, Støy J, Steiner DF, Philipson LH, Bell GI; Neonatal Diabetes International Collaborative Group, Hattersley AT, Ellard S. Insulin mutation screening in 1044 patients with diabetes: mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood. Diabetes 2008;57:1034-1042.
4. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, Howard N, Srinivasan S, Silva JM, Molnes J, Edghill EL, Frayling TM, Temple IK, Mackay D, Shield JP, Sumnik Z, van Rhijn A, Wales JK, Clark P, Gorman S, Aisenberg J, Ellard S, Njolstad PR, Ashcroft FM, Hattersley AT. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-1849.
5. Proks P, Arnold AL, Bruining J, Girard C, Flanagan SE, Larkin B, Colclough K, Hattersley AT, Ashcroft FM, Ellard S. A heterozygous activating mutation in the sulphonylurea receptor (SUR1) (ABCC8) causes neonatal diabetes. Hum Mol Genet 2006; 15:1793-1800.
6. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, Bryan J, Aguilar-Bryan L, Vaxillaire M, Froguel P. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006;355:456-466.
7. Støy J, Edghill EL, Flanagan SE, Ye H, Paz VP, Pluzhnikov A, Below JE, Hayes MG, Cox NJ, Lipkind GM, Lipton RB, Greeley SA, Patch AM, Ellard S, Steiner DF, Hattersley AT, Philipson LH, Bell GI; Neonatal Diabetes International Collaborative Group. Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 2007;104:15040-15044.
8. Polak M, Cave H. Neonatal diabetes mellitus: a disease linked to multiple mechanisms. Orphanet J Rare Dis 2007;2:12.
9. Darendeliler F, Fournet JC, Bas F, Junien C, Gross MS, Bundak R, Saka N, Gunoz H. ABCC8 (SUR1) and KCNJ11 (KIR6.2) mutations persistent hyperinsulinemic hypoglycemia of infancy and evaluation of different therapeutic measures. J Pediatr Endocrinol Metab 2002;15:993-1000.
10. Pearson ER, Flechtner I, Njølstad PR, Malecki MT, Flanagan SE, Larkin B, Ashcroft FM, Klimes I, Codner E, Iotova V, Slingerland AS, Shield J, Robert JJ, Holst JJ, Clark PM, Ellard S, Søvik O, Polak M, Hattersley AT; Neonatal Diabetes International Collaborative Group. Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 2006;355:467-477.
11. Rafiq M, Flanagan SE, Patch AM, Shields BM, Ellard S, Hattersley AT; Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31:204-209.
12. Ellard S, Flanagan SE, Girard CA, Patch AM, Harries LW, Parrish A, Edghill EL, Mackay DJ, Proks P, Shimomura K, Haberland H, Carson DJ, Shield JP, Hattersley AT, Ashcroft FM. Permanent Neonatal Diabetes Caused by Dominant, Recessive, or Compound Heterozygous SUR1 Mutations with Opposite Functional Effects. Am J Hum Genet 2007;81:375-382.
13. The Global IDF/ISPAD Guideline For Diabetes in Childhood And Adolescence. International Diabetes Federation 2011; ISBN 2-930229-72-1.
14. Zwaveling-Soonawala N, Hagebeuk EE, Slingerland AS, Ris-Stalpers C, Vulsma T, van Trotsenburg AS. Successful transfer to sulfonylurea therapy in an infant with developmental delay, epilepsy and neonatal diabetes (DEND) syndrome and a novel ABCC8 gene mutation. Diabetologia 2011;54:469-471.
15. ATP channel) gene are associated with a variable clinical phenotype. Clin Endocrinol (Oxf) 2009;71:358-362.
16. Russo C, Salina A, Aloi C, Iafusco D, Lorini R, d'Annunzio G. Mother and daughter carrying the same KCNJ11 mutation but with a different response to switching from insulin to sulfonylurea. Diabetes Res Clin Pract 2011;94:50-52.
17. Landau Z, Wainstein J, Hanukoglu A, Tuval M, Lavie J, Glaser B. Sulfonylurea-responsive diabetes in childhood. J Pediatr 2007;150:553-555.
18. Lafusco D, Bizzarri C, Cadario F, Pesavento R, Tonini G, Tumini S, Cauvin V, Colombo C, Bonfanti R, Barbetti F. No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes. Diabetologia 2011;54:2736-2738.
19. Jónasson G, Carlsen KH, Sødal A, Jonasson C, Mowinckel P. Patient compliance in a clinical trial with inhaled budesonide in children with mild asthma. Eur Respir J 1999;14:150-154.